PDCD1 and neoplasm: The cotreatment of RCE plus Oxa caused no significant change in the body weight and blood biochemistry in the liver or kidneys in human PD-1/PD-L1 MC38 tumor mouse models, suggesting the safety and good tolerance of the co-therapy to some extent (Figure 3).